Saturday, June 25, 2016

Cellectar shows potential against triple negative breast cancer

Cellectar shows potential against triple negative breast cancer

June 23, 2016 by · Leave a Comment 

Tweet Cellectar Biosciences (NASDAQ:CLRB) has announced the results of the first phase of a NCI-funded Small Business Innovation Research (SBIR) Phase 1 contract for a study of CLR 125, a radiotherapeutic isotope, which may be suited to treat micro-metastatic disease, conjugated to the company’s proprietary phospholipid drug conjugate (PDC) delivery platform. The study demonstrated that […]

Anavex gets orphan drug status for infantile spasms

Anavex gets orphan drug status for infantile spasms

June 22, 2016 by · Leave a Comment 

Tweet Anavex Life Sciences (NASDAQ:AVXL) has received FDA orphan drug designation for ANAVEX 2-73 for the treatment of infantile spasms. ANAVEX 2-73 already has orphan drug designation for the treatment of Rett syndrome. An infantile spasm is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. […]

Oramed gets milestone payment from HTIT

Oramed gets milestone payment from HTIT

June 21, 2016 by · Leave a Comment 

Tweet Oramed Pharmaceuticals (NASDAQ:ORMP) has received a $6.5-million milestone payment from Hefei Tianhui Incubator of Technologies (HTIT) under a December 2015 license and investment agreement. The payment follows Oramed’s positive top-line results from its Phase 2b U.S. trial designed to evaluate the safety and efficacy of its oral insulin capsule ORMD-0801 in patients with Type […]

Dipexium Pharma presents new Locilex microbiology data

Dipexium Pharma presents new Locilex microbiology data

June 20, 2016 by · Leave a Comment 

Tweet Dipexium Pharmaceuticals (NASDAQ:DPRX) and research collaborator, R. M. Alden Research Laboratory, presented data from two new Locilex microbiology studies at the American Society for Microbiology’s Microbe conference in Boston. In the first poster presentation, researchers concluded that pexiganan, the active pharmaceutical ingredient in Locilex, demonstrated a high level of activity against a diverse group […]

Titan Pharma gains more media attention

Titan Pharma gains more media attention

June 20, 2016 by · Leave a Comment 

Tweet NBC News has become the latest media outlet to feature Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant for people addicted to heroin and prescription painkillers. As an implantable version of oral buprenorphine, which is a drug designed to ease withdrawal symptoms, FDA-approved Probuphine is a new hope for those caught in the fight of their lives […]

WB ups ARIAD price target to $12

WB ups ARIAD price target to $12

June 20, 2016 by · Leave a Comment 

Tweet William Blair has raised it price target for ARIAD Pharmaceuticals (NASDAQ:ARIA) to $12 from $10 after an analyst day on Friday where the company discussed the outcome of its strategic review. The stock was quoted at $7.59 on Monday afternoon. The strategic review included ARIAD’s commitment to financial discipline and its refined focus on […]

First patients treated with Titan Pharma’s Probuphine

First patients treated with Titan Pharma’s Probuphine

June 20, 2016 by · Leave a Comment 

Tweet The first 10 patients received treatment last week with Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine, following FDA approval on May 26. Probuphine was developed using Titan’s long-term, continuous drug delivery platform, ProNeura, for the maintenance treatment of opioid dependence. To date, more than 1,000 health care providers in 44 states have been trained […]

Roth starts Heat Biologics at buy

Roth starts Heat Biologics at buy

June 20, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $2.75 price target. The stock closed at 60 cents on Friday. “Heat Biologics possesses a portfolio of unique, differentiated vaccines that, in our opinion, could bring a much needed boost to the cancer vaccine space, which has been plagued […]

Roth starts PhaseRx at buy

Roth starts PhaseRx at buy

June 17, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of PhaseRx (NASDAQ:PZRX) with a “buy” rating and 12-month price target of $8. The stock closed at $5 on Thursday. “In our opinion, PhaseRx’s technology platform, combined with promising preclinical results, first mover advantage in the multi-billion dollar i-ERT market opportunity, a number of potential upcoming milestones, and […]

Juniper Pharma COL-1077 Phase 1 data published

Juniper Pharma COL-1077 Phase 1 data published

June 17, 2016 by · Leave a Comment 

Tweet The peer-reviewed medical journal, Clinical Pharmacology in Drug Development, has published the combined results of two Phase 1 clinical trials by Juniper Pharmaceuticals (NASDAQ:JNP) that demonstrated the safety and pharmacokinetics of Juniper’s lidocaine bioadhesive vaginal gel, COL-1077. The article reports that in women treated with COL-1077, lidocaine was absorbed through vaginal tissue and into […]

Next Page »

Email Newsletters with Constant Contact
Google+